Deuterated isoquinolinylpropionamide derivatives useful as kinase inhibitors

Deuterated isoquinolinylpropionamide derivatives provide a solution to the slow degradation issue of current ROCK and PKCθ inhibitors by enhancing metabolic stability and potency, effectively treating associated diseases like pulmonary hypertension and cancer.

WO2026241736A1PCT designated stage Publication Date: 2026-11-19BRIM BIOTECH INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028553
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-16
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current ROCK and PKCθ inhibitors have slow degradation rates, leading to undesired side effects when administered systemically, and there is a need for more potent and metabolically labile compounds to treat associated diseases effectively and safely.

Method used

Development of deuterated isoquinolinylpropionamide derivatives with specific structures that act as potent inhibitors of ROCK and PKCθ, including enantiomers, racemic mixtures, and isotope variants, which are more metabolically stable and have improved inhibitory activity.

Benefits of technology

These compounds demonstrate enhanced kinase inhibition potency and metabolic stability, offering a safer and more effective therapeutic approach for treating diseases associated with ROCK and PKCθ, such as pulmonary hypertension, cancer, and eye disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028553_19112026_PF_FP_ABST
    Figure US2026028553_19112026_PF_FP_ABST
Patent Text Reader

Abstract

A compound of Formula (I), an enantiomer thereof, a racemic mixture thereof, an isotope variant thereof, or a salt thereof, wherein the compound has the following structure: Formula (I), wherein R is hydrogen or R'–CO–, wherein R' is a C1-C6 alkyl or a C6-C10 aryl, wherein the C1-C6 alkyl is a straight-chain alkyl, a branched-chain alkyl, or a cyclic alkyl, and wherein the C6-C10 aryl is an aromatic moiety with one or more optional substitutions selected from the group consisting of C1-C6 alkyl, halogen, and OR", wherein R" is hydrogen or C1-C6 alkyl. A pharmaceutical composition for treating a ROCK or PKCθ associated disease includes a compound of Formula (I) and a pharmaceutically acceptable excipient.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No.: PPD23-PCTDEUTERATED ISOQUINOLINYLPROPIONAMIDE DERIVATIVES USEFUL AS KINASE INHIBITORSBACKGROUND OF INVENTIONField of the Invention

[0001] The present invention relates to novel compounds for inhibiting Rho-associated protein kinase (ROCK) and Protein kinase C-theta (PKC9), methods of preparing such compounds, pharmaceutical compositions containing the same, and therapeutic uses thereof.Background Art

[0002] Rho-associated protein kinase (ROCK) belongs to the AGC (PKA / PKG / PKC) family of serine-threonine kinases. Two human isoforms of ROCK have been described, ROCK-I and ROCK-II. ROCK is expressed in many human organs including the heart, pancreas, lung, liver, skeletal muscle, kidney and brain. In patients with pulmonary hypertension, ROCK activity is significantly higher in lung tissues and circulating neutrophils (Duong-Quy S, Bei Y, Liu Z, Dinh-Xuan AT. Role of Rho-kinase and its inhibitors in pulmonary hypertension. Pharmacol Ther. 2013; 137(3):352-64). A significant correlation has also been reported between neutrophil ROCK activity and the severity and duration of pulmonary hypertension (Duong-Quy et al., 2013).

[0003] ROCK is involved in many pathways that contribute to the pathologies associated with several acute and chronic pulmonary diseases, including asthma, COPD, bronchiectasis and ARDS / ALI. Thus, inhibitors of ROCK (ROCKi) have the potential to treat a number of pathological mechanisms in respiratory diseases (Fernandes L B, Henry P J, Goldie R G. Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2007 October; 1 (1 ):25-33). For example, known ROCKi Y-27632 has been demonstrated to facilitate bronchodilatation and reduce pulmonary eosinophilia trafficking and airway hyperresponsiveness (Gosens, R.; Schaafsma, D.; Nel emans, S. A.; Halayko, A. J. Rho kinase as a drug target for the treatment of airway hyperresponsiveness in asthma. Mini-Rev. Med. Chem. 2006, 6, 339-348). Pulmonary ROCK activation has also been demonstrated in humans with idiopathic pulmonary fibrosis (IPF) and in animal models of this disease. ROCK inhibitors can prevent fibrosis in these models and, more remarkably, induce the regression of alreadyAttorney Docket No.: PPD23-PCTestablished fibrosis, thus indicating ROCK inhibitors as potential powerful pharmacological agents to halt progression of pulmonary fibrosis (Jiang, C.; Huang, H.; Liu, J.; Wang, Y.; Lu, Z.; Xu, Z. Fasudil, a rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice. Int. J. Mol. Sci. 2012, 13, 8293-8307).

[0004] ROCK is also highly expressed in several cancers, such as renal clear cell carcinoma (RCC), esophageal carcinoma (ESCA), acute myeloid leukemia (AML), and stomach adenocarcinoma (ST AD).

[0005] Four ROCK inhibitors (ROCKi) are approved for clinical use. Fasudil is approved for treating cerebral vasospasm and delayed cerebral ischemic symptoms in Japan and China. Ripasudil is approved for treating ocular hypertension and open-angle glaucoma in Japan. Netarsudil is approved for reducing elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension in the U.S. and EU. Belumosudil is approved for treating chronic graft-versus-host disease (cGvHD) in the U.S.

[0006] Protein kinase C-theta (PKC9) is a serine / threonine kinase mainly expressed in hematopoietic cells and plays a role in signal transduction. PKC9 is important for T-cell activation. Study using PKC9 knock-out mice revealed that PKC9 is involved in activity-dependent synapse refinement and elimination at the neuromuscular junction. (M.X. Li et al., The Role of the Theta Isoform of Protein Kinase C (PKC) in Activity-Dependent Synapse Elimination: Evidence from the PKC Theta Knock-Out Mouse In Vivo and In Vitro, J. Neuroscience, 2004, 24(15): 3762-3769).

[0007] Given the plethora of diseases and human afflictions that can be addressed or prevented by inhibitors of ROCK and PKC9, there is a need for effective and safe inhibitors of ROCK and PKC9 for therapeutic uses.SUMMARY OF THE INVENTION

[0008] In one aspect, embodiments of the invention relate to a compound of Formula (I), an enantiomer thereof, a racemic mixture thereof, an isotope variant thereof, or a salt thereof, wherein the compound has the following structure:Attorney Docket No.: PPD23-PCTZORFormula (I)wherein R is hydrogen or R’-CO- wherein R’ is a Ci-Ce alkyl or a Ce-Cio aryl, wherein the Ci-CG alkyl is a straight-chain alkyl, a branched-chain alkyl, or a cyclic alkyl, and wherein the Ce-Cio aryl is an aromatic moiety with one or more optional substitutions selected from the group consisting of Ci-Ce alkyl, halogen, and OR”, wherein R” is hydrogen or Ci-Ce alkyl.

[0009] In accordance with some embodiments of the invention, R is hydrogen in Formula (I) and the compound is referred to as “Compound 1.” In accordance with some embodiments of the invention, R is 2,4-dimethylbenzoyl in Formula (I) and the compound is referred to as “Compound 2.”

[0010] In one aspect, embodiments of the invention relate to pharmaceutical compositions comprising a compound of Formula (I), or a stereoisomer, enantiomer, mixture of enantiomers, or isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient.

[0011] In one aspect, embodiments of the invention relate to a method of treating, a ROCK or PKC9 mediated disease in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a stereoisomer, enantiomer, mixture of enantiomers, or isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0012] In according to any of the above embodiments of the invention, the disease is chosen from, but not limited to, acute and chronic pulmonary diseases, idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension, cancer, chronic graft-versus-host disease (cGvHD), and eye disorders including but not limited to glaucoma, pterygium, neovascular age-related macular degeneration, diabetic macular edema, neurotrophic keratitis, corneal endothelial cell dystrophy, corneal neuropathy, corneal nerve regeneration after penetrating eye surgery, and corneal nerve damage after refractive eye surgery.Attorney Docket No.: PPD23-PCT

[0013] In one aspect, embodiments of the invention relate to a method of modulating kinase activity, comprising contacting a kinase with a therapeutically effective amount of Compound 1 or a stereoisomer, enantiomer, mixture of enantiomers, tautomer, mixture of tautomers, or isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0014] Other aspects of the invention would become apparent with the following detailed description and the associated drawings.BRIEF DESCRIPTION OF THE DRAWINGS

[0015] FIG. 1 shows in vitro ROCK1, ROCK2 and PKC9 kinase inhibition activities of Compound 1, Ml, and Netarsudil. Data are presented as ICso (concentration required for 50% inhibition).

[0016] FIG. 2 shows results from microsomal stability studies of Compound 1 and Ml. Data are presented as % remaining at each timepoint.

[0017] FIG. 3 shows results of intrinsic metabolic profiles of Compound 1 and Ml. Data are presented as values of percentage of parent compound remaining over time and the calculated pharmacokinetic parameters, including the first-order degradation rate constant (-k), in vitro halflife (ti / a, minutes), and intrinsic clearance (Cunt) expressed as pL / min / mg protein and scaled to mL / min / kg body weight.DETAIL DESCRIPTION OF THE INVENTION

[0018] Embodiments of the invention relate to a compound of Formula (I) or an enantiomer thereof, a racemic mixture thereof, or an isotope variant thereof. These compounds are potent inhibitors of ROCK and PKC0 and can be used as pharmaceuticals for treating diseases associated with ROCK and PKC0. ROCK is a clinically validated target for various indications. However, due to slow degradation (i.e., metabolically stable) of existing drugs, they can have undesired side effects, especially when administered systemically. Compounds of Formula (I) are more metabolically labile and more potent inhibitors than existing drugs. Therefore, compounds of Formula (I) would be more suitable for treating ROCK and / or PKC0 associated diseases, especially in systemic setting.

[0019] Compounds of Formula (I) have the following structure:Attorney Docket No.: PPD23-PCT,0RT H ? ?O D Iv,TvFormula (I)D Dwherein R is hydrogen or R’-CO- wherein R’ is a Ci-Ce alkyl or a Ce-Cio aryl,wherein the Ci-Ce alkyl is a straight-chain alkyl, a branched-chain alkyl, or a cyclic alkyl, andwherein the Ce-Cio aryl is an aromatic moiety with one or more optional substitutions selected from the group consisting of Ci-Ce alkyl, halogen, and OR”, wherein R” is hydrogen or Ci-Ce alkyl.

[0020] A compound of Formula (I) has one chiral center. Embodiments of the invention encompass either optical isomer (R-enantiomer or S-enantiomer) and a racemic mixture. In preferred embodiments, the compounds are S-enantiomers as shown below.

[0021] Compounds of Formula (I) of the invention also include isotope variants thereof. Such isotope variants, for example, may include oxygen isotope (e.g.,17O,18O), nitrogen isotope (e.g.,13N,15N), and carbon isotope (e.g.,13C,14C). These isotope variants may be used in diagnostic or tracing applications.

[0022] In a preferred embodiment of the invention, R is hydrogen in the above Formula (I) and the compound is herein referred to as Compound 1, which may be either enantiomer or a racemic mixture. The following is the S-enantiomer of Compound 1.Attorney Docket No.: PPD23-PCT OHD DCompound 1 (S-enantiomer)

[0023] In some embodiments of the invention, R is R’-CO-. These compounds are esters of the benzyl alcohol of Compound 1. It is known that such esters can be hydrolyzed in vivo to release Compound 1. An example of such ester hydrolysis in vivo is Netarsudil, which is hydrolyzed to release an active metabolite (herein referred to as Ml). Thus, these ester compounds may be considered as prodrugs of Compound 1.

[0024] In a preferred embodiment of the invention, R is 2,4-dimethylbenzoyl (i.e., R = R’- CO-, wherein R’ = 2,4-dimethylphenyl) in the above Formula (I) and the compound is herein referred to as Compound 2, which may be either enantiomer or a racemic mixture. The following is the S-enantiomer of Compound 2.D DCompound 2 (S-enantiomer)

[0025] Compounds provided herein contain a basic moiety (-NH2) and so it may also be provided as a pharmaceutically acceptable salt. See, Berge et al, J. Pharm. Sci. 1977, 66, 1-19; and Handbook of Pharmaceutical Salts, Properties, and Use; Stahl and Wermuth, Ed.; Wiley-VCH and VHCA: Zurich, Switzerland, 2002.

[0026] Suitable acids for use in the preparation of pharmaceutically acceptable salts include, but are not limited to, acetic acid, 2,2-dichloroacetic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, boric acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(l,S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, cyclohexanesulfamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid,Attorney Docket No.: PPD23-PCTglucoheptonic acid, D-gluconic acid, D-glucuronic acid, L-glutamic acid, a-oxoglutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, (+)-L-lactic acid, (±)-DL-lactic acid, lactobionic acid, lauric acid, maleic acid, (-)-L-malic acid, malonic acid, (±)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene- 1,5-disulfonic acid, l-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, perchloric acid, phosphoric acid, L-pyroglutamic acid, saccharic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid, and valeric acid.

[0027] Compounds of the invention may also be provided as a prodrug, which is a functional derivative of Compounds of Formula (I) and is readily convertible into Compound 1 in vivo. For example, the amino group (-NH2) may be derivatized as an amide that is readily cleaved by a protease.Method of Synthesis

[0028] Compounds of Formula (I) may be synthesized using procedures similar to the published procedures (eg., M.A. deLong and J.M. Sturdivant, “Asymmetric Synthesis of Netarsudil: A New Therapeutic for Open-Angle Glaucoma,” Synthesis, 2019; 51(04): 953-959; DOI: 10.1055 / s-0037-1610310 or J.M. Sturdivant et al., Bioorg. Med. Lett. 26 (2016), 2475-2480). To obtain the deuterated compounds of Formula (I), deuterated 6-aminoisoquinoline is used instead of 6-aminoisoquinoline as a reagent.

[0029] The following exemplary synthetic scheme is based on the procedures of the above-mentioned Bioorg. Med. Lett. 26 (2016), 2475-2480:Attorney Docket No.: PPD23-PCTSynthesis proceduresStep 1: Prepare methyl [4-(hydroxymethyl)phenyl] acetate

[0030] To a solution of [4-(hydroxymethyl)phenyl]acetic acid (100 g, 0.6 mol) in MeOH (2 L) was added acetyl chloride(100 mg, 1.2 mol). The reaction was stirred for 2 h at 25 °C. The reaction was completed detected by TLC(PE:EtOAc=10:l) . The residue was partitioned between ethyl acetate (500 mL) and water (500 mL). The aqueous layer was extracted with ethyl acetate (500 mL X 3). The organic layer was washed with brine, dried over Na SO4 and evaporated under reduced pressure to obtain methyl [4-(hydroxymethyl)phenyl]acetate (80 g, yield: 74.07 %) as a yellow oil. The residue was used directly for the next step without purification.Step 2: Prepare methyl {4-[4-methyl-3,3-di(prop-2-yl)-2-oxa-3-silapent-l-yl]phenyl}acetate

[0031] To a solution of methyl [4-(hydroxymethyl)phenyl]acetate (80 g, 0.44 mol) in DMF (0.8 L) was added triethylamine(68 g, 0.67 mol) and triisopropyl silyl chloride(94 g, 0.49 mol) at 0°C . The reaction was stirred for 12 h at 25 °C. The residue was partitioned between ethyl acetate (500 mb) and water (500 mL). The aqueous layer was extracted with ethyl acetate (500 mb x 3). The organic layer was washed with brine, water, dried over Na2SC>4 and evaporated under reducedAttorney Docket No.: PPD23-PCTpressure. The residue was purified by flash chromatography over silica gel (PE / EA 0: 100 to PE / EA 10:1) to give methyl {4-[4-methyl-3,3-di(prop-2-yl)-2-oxa-3-silapent-l-yl]phenyl}acetate (100 g, yield: 67.6 %) as a yellow oil.

[0032] 'H NMR (400 MHz, CDC13) 87.32 (d, J = 7.9 Hz, 2H), 7.24 (d, J = 7.7 Hz, 2H), 4.82 (s, 2H), 3.69 (s, 3H), 3.62 (s, 2H), 1.23 - 1.13 (m, 3H), 1.09 (d, J= 6.7 Hz, 18H).Step 3: Prepare methyl 3-(l,3-dioxo-2,3-dihydro-LH-isoindol-2-yl) -2-{4-[4-methyl-3,3-di (prop-2-yl)-2-oxa-3-silapent-l-yl]phenyl} propanoate

[0033] To a solution of methyl {4-[4-methyl-3,3-di(prop-2-yl)-2-oxa-3-silapent-l-yl]phenyl} acetate (30 g, 0.089 mol) in THF (300 mb) was added LiHMDS (134 mL, 0.134 mol) dropwise at -78 °C under N2 atmosphere, and the mixture was stirred at -78 °C for 0.5 h. A solution of N-(bromomethyl)phthalimide (32 g, 0.134 mol) in THF (300 mL) was added dropwise, keeping the temperature below -78 °C. Then the mixture was allowed to rise to room temperature slowly. The reaction mixture was stirred at room temperature for 2 h and followed by TLC (PE:EtOAc=10:l) . The reaction was quenched with water (200 mL), then extracted with ethyl acetate (2X300 mL). The organic extracts were combined, washed with brine (100 mL), dried with anhydrous Na2SC>4, and concentrated under reduced pressure. The residue was purified by silica gel column (hexane:ethyl acetate = 100:0-10:1) to give methyl 3-(l,3-dioxo-2,3-dihydro-1 7-isoindol-2-yl) -2- {4-[4-methyl-3,3-di(prop-2-yl)-2-oxa-3-silapent-l-yl] phenyl} propanoate (20 g, yield: 45.4 %) as a brown solid.Step 4: Prepare methyl 3-amino-2- {4-[4-methyl-3,3-di(prop-2-yl)-2-oxa-3-silapent-l-yl] phenyl} propanoate

[0034] To a solution of methyl 3-(l,3-dioxo-2,3-dihydro-1 7-isoindol-2-yl) -2- {4-[4-methyl-3,3-di(prop-2-yl) -2-oxa-3 -silapent- 1-yl] phenyl} propanoate (20 g, 0.040 mol) in 200 mL acetonitrile was added 80% Hydrazine hydrate (10 g, 0.2 mol), the reaction mixture was heated to 70 °C and stirred for 1.5 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure, the residue was used to next step without further purification. LC-MS: m / z [M+H] = 366.5.Step 5: Prepare methyl 2- {4-[4-methyl-3,3-di(prop-2-yl) -2-oxa-3-silapent-l-yl]phenyl} -3-({[(2-methylprop-2-yl) oxy] carbonyl} amino)propanoateAttorney Docket No.: PPD23-PCT

[0035] To a solution of methyl 3-amino-2- {4-[4-methyl-3,3-di(prop-2-yl) -2-oxa-3-silapent-l-yl] phenyl) propanoate (15 g, 0.041 mol) in CH2CI2 (150 mL) was added di-Zc / 7-butyl dicarbonate (9.83 g, 0.045 mol) at 0 °C, then 4-dimethylaminopyridine (504 mg, 4.1 mmol) was added. The mixture was stirred for 2 hours at room temperature. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column (hexane:ethyl acetate = 100:0-10:1) to give methyl 2-{4-[4-methyl-3,3-di(prop-2-yl) -2-oxa-3 -silapent- l-yl]phenyl) -3-({[(2-methylprop-2-yl)oxy] carbonyl (amino) propanoate (18 g, yield: 94.2 %) as a brown solid. LC-MS: m / z [M+Na] = 488.5.Step 6: Prepare 2-{4-[4-methyl-3,3-di(prop-2-yl) -2-oxa-3-silapent-l-yl]phenyl} -3- ({[(2-methylprop-2-yl) oxy] carbonyl} amino)propanoic acid

[0036] To a solution of methyl 2-{4-[4-methyl-3,3-di(prop-2-yl)-2-oxa-3-silapent-l-yl]phenyl) -3-({[(2-methylprop-2-yl)oxy]carbonyl)amino) propanoate (18 g, 0.039 mol) in 100 mL methanol and 100 mL THF and 50 mL water was added lithium hydroxide monohydrate (4.9 g, 0.117 mol), the mixture was stirred 2 hours at room temperature. The mixture was acidified with aqueous HC1, then extracted with ethyl acetate (3 X 100 mL). The organic extracts were combined, washed with brine (100 mL), dried with anhydrous ISfeSCh, and concentrated under reduced pressure. The residue was purified by silica gel column (hexane:ethyl acetate = 100:0-1 :2) to give 2-{4-[4-methyl-3,3-di(prop-2-yl) -2-oxa-3 -silapent- l-yl]phenyl) -3- ({[(2-methylprop-2-yl)oxy]carbonyl)amino)propanoic acid (15 g, yield: 85.2 %) as a white solid. LC-MS: m / z [M+Na] = 474.6.

[0037] JH NMR (400 MHz, Chloroform-d) 57.34 (d, J = 8.0 Hz, 2H), 7.24 (s, 2H), 6.85 (s, 0.5H), 4.96 (d, J = 28.3 Hz, 0.5H), 4.82 (s, 2H), 3.86 (d, J = 38.5 Hz, 1H), 3.55 (d, J = 35.7 Hz, 2H), 1.45 (s, 9H),1.24- 1.13 (m, 3H), 1.09 (d, J = 6.7 Hz, 18H).Step 7: Prepare 2-methyIpropan-2-yl ({3-[(l,3,4,5,7,8-2He) isoquinolin-6-ylamino] -2- {4-[4-methyl-3,3-di(prop-2-yl)-2-oxa-3-silapent-l-yl] phenyl} -3-oxopropyl} amino) methanoate

[0038] To a solution of 2-{4-[4-methyl-3,3-di(prop-2-yl) -2-oxa-3-silapent-l-yl]phenyl} - 3- ({[(2-methylprop-2-yl)oxy]carbonyl}amino)propanoic acid (350 mg, 0.78 mmol) in CH3CN (2 mL) was added (l,3,4,5,7,8-2H6)isoquinolin-6-amine(100 mg, 0.67 mmol), NMI (224 mg, 2.70 mmol) and TCFH (266 mg, 0.95 mmol) . The reaction was stirred for 2 h at 25 °C and thenAttorney Docket No.: PPD23-PCTpartitioned between ethyl acetate (50 mL) and water (50 mL). The aqueous layer was extracted with ethyl acetate (50 mL X 3). The combined organic extracts were washed with brine, dried over Na2SC>4, and evaporated under reduced pressure. The residue was purified by flash chromatography over silica gel (PE / EA 0:100 to PE / EA 2:1) to give 2-methylpropan-2-yl ({3-[(l,3,4,5,7,8-2H6)isoquinolin-6-ylamino] -2-{4-[4-methyl-3,3-di(prop-2-yl)-2-oxa-3-silapent-l-yl]phenyl} -3 -oxopropyl }amino)methanoate (416 mg, yield: 92.03 %) as a brown solid. LC-MS: m / z [M+H] = 584.1.Step 8: Prepare 2-methylpropan-2-yl ({3-[(l,3,4,5,7,8-2H6)isoquinolin-6-ylamino] -2-[4-(hydroxymethyl)phenyl]-3-oxopropyl}amino)methanoate

[0039] To a solution of 2-methylpropan-2-yl ({3-[(l,3,4,5,7,8-2H6)isoquinolin-6-ylamino] -2- {4-[4-methyl-3 ,3 -di(prop-2-yl)-2-oxa-3 -silapent- 1 -yl]phenyl }-3 -oxopropyl } amino)-methanoate (416 mg, 0.71 mmol) in THF (6 mL) was added TBAF (1.38 mL, 1.38 mmol, IM in THF) . The reaction was stirred for 12 h at 35 °C. The reaction was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (50 mL) and water (50 mL). The aqueous layer was extracted with ethyl acetate (50 mL * 3). The combined organic extracts were washed with water (50 mL x 3), dried over Na2SC>4, and evaporated under reduced pressure. The residue was purified by flash chromatography over silica gel (DCM / MeOH 100:0 to DCM / MeOH 15:1) to give 2-methylpropan-2-yl ({3-[(l,3,4,5,7,8-2H6)isoquinolin-6-ylamino]-2-[4-(hydroxymethyl)phenyl]-3-oxopropyl}-amino)methanoate(268 mg, yield: 88.11 %). LC-MS: m / z [M+H] = 428.4.Step 9: Prepare / V-(l, 3, 4,5,7, 8-2He) isoquiiiolin-6-yl-3-amino-2-[4-(hydroxymethyl)phenyl] propanamide dihydrochloride

[0040] To a solution of 2-methylpropan-2-yl ({3-[(l,3,4,5,7,8-2H6)isoquinolin-6-ylamino] -2- [4-(hydroxymethyl)phenyl]-3-oxopropyl}amino)methanoate (268 mg, 0.63 mmol ) in THF (5 mL) was added HC1 in dioxane (1.2 mL, 4.8 mmol, 4 M). The reaction was stirred for 12 h at 25 °C. The solid was filtered and purified by slurring with THF to give / V-(l,3,4,5,7,8-2He) isoquinolin-6-yl-3-amino-2- [4-(hydroxymethyl)phenyl] propanamide dihydrochloride (150 mg, yield: 60.3 %) as a white solid (Compound 1; BR16002). LC-MS: m / z [M+H] = 328.3.Attorney Docket No.: PPD23-PCT

[0041] 'H NMR (400 MHz, Methanol-^) 87.51 - 7.40 (m, 4H), 4.60 (s, 2H), 4.32 (dd, J = 8.8, 5.5 Hz, 1H), 3.72 - 3.66 (m, 1H), 3.28 (d, J= 5.4 Hz, 1H).13C NMR (101 MHz, MeOD) 8 170.90, 146.07, 142.11, 140.56, 134.01, 127.87, 127.57, 123.74, 66.74, 63.18, 50.14, 41.46.

[0042] The above synthetic scheme illustrates procedures for preparing Compound 1 (BR16002). Other compounds of Formula (I) may be synthesized with minor modifications of this synthetic scheme - i.e., before the final deprotection of the BOC group, the benzyl alcohol may be converted into an ester by reacting with an acyl halide or anhydride. For example, Compound 2 may be prepared by esterification of the benzyl alcohol using 2,4-dimethylbenzoyl chloride, followed by deprotection of the BOC group.

[0043] The above synthetic scheme will result in a racemic mixture of compounds of Formula (I). Conventional techniques for the isolation of individual enantiomers include resolution of a racemic mixture using, for example, chiral chromatography, recrystallization, resolution, diastereomeric salt formation, or derivatization into diastereomeric adducts followed by separation.

[0044] Alternatively, one may use an asymmetric synthesis scheme to obtain the desired enantiomer. An asymmetric synthesis of Netarsudil has been published. (M.A. deLong and J.M. Sturdivant, “ Asymmetric Synthesis of Netarsudil: A New Therapeutic for Open-Angle Glaucoma,’’'’ Synthesis, 2019; 51(04): 953-959; DOI: 10.1055 / s-0037-1610310). These procedures can be used to prepare enantiomers of compounds of Formula (I).Pharmaceutical Compositions

[0045] Provided herein are pharmaceutical compositions comprising Compounds of Formula (I) as an active ingredient, including a stereoisomer, enantiomer, mixture of enantiomers, or isotope variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and one or more pharmaceutically acceptable excipients. Suitable excipients are well known in the art, including diluents, binders, disintegrants, preservatives, etc.

[0046] The compound provided herein may be administered alone, or in combination with another active ingredient. The pharmaceutical compositions that comprise a compound provided herein, e.g., Compound 1 or Compound 2 including a stereoisomer, enantiomer, mixture of enantiomers, or isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, can be formulated in various dosage forms for oral, parenteral, and topicalAttorney Docket No.: PPD23-PCTadministration. The pharmaceutical compositions can also be formulated as modified release dosage forms. These dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art.

[0047] The pharmaceutical compositions provided herein can be administered at once, or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the patient being treated, and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations.

[0048] Some embodiments of the invention relate to the use of such pharmaceutical compositions in the treatment of ROCK and / or PKC9 associated diseases. Compounds of the invention are deuterated analogs of known ROCK inhibitors, such as Netarsudil and Ml, and can be used to treat the same ROCK-associated diseases. For example, ROCK inhibitor Y27632 was shown to be effective for treating pterygium (Dai J. et al., Sci. Rep. 2024, 14:30930, PMID: 39730553). Y27632 is also effective for treating neurotrophic keratitis, corneal endothelial cell dystrophy, and corneal neuropathy (Mertsch S. et a;. Ocul. Surf. 2021; 22:213-223. PMID: 34419637), as well as corneal nerve regeneration after penetrating eye surgery (OkumuraN. et al. Invest. Ophthalmol. Vis. Sci. 2016, 57(3): 1284-92. PMID: 26998714). Ripasudil is effective for treating corneal endothelial cell dystrophy and corneal nerve regeneration after penetrating eye surgery. Netarsudil is effective for treating glaucoma and corneal endothelial cell dystrophy (Casanova MI et al. Sci. Rep. 2024, 14:6238. Doi: 10.1038 / s41598-024-56084-4). Ml (AR-13503) is effective for treating neovascular age-related macular degeneration and diabetic macular edema (Aerie Pharmaceuticals clinical trial: NCT03835884).

[0049] Embodiments of the invention will be further illustrated with the following specific examples, which are for lustration only and are not intended to limit the scope of the invention. One skilled in the art would appreciate that besides these specific examples, other variations and modifications are possible.EXAMPLES ROCK Kinase AssayAttorney Docket No.: PPD23-PCT

[0050] The inhibitory activities of test compounds against ROCK1 and ROCK2 were evaluated using the ADP-Glo™ Kinase Assay (Promega), a luminescence-based method that quantifies ADP produced during kinase reactions. Each assay was performed in a 384-well plate with a total volume of 5 pL per well, containing kinase buffer (40 mM Tris-HCl, pH 7.5, 20 mM MgCh, 0.01% Triton X-100, 1 mM DTT), 5 pM ATP, and 0.2 pg / pL of the peptide substrate S6Ktide. Recombinant ROCK1 and ROCK2 enzymes were added at 0.2 ng / well and 0.5 ng / well, respectively. Test compounds, prepared in DMSO, were added at various concentrations and preincubated with the enzymes for 5 minutes at room temperature. The reaction was initiated by adding ATP and substrate, followed by incubation for 60 minutes in the dark. Subsequently, 5 pL of ADP-Glo™ Reagent was added to stop the reaction and remove unconsumed ATP, and after a 40-minute incubation, 10 pL of Kinase Detection Reagent was added. The plate was incubated for another 30 minutes at room temperature before luminescence was measured using a PerkinElmer Ensight plate reader with a 0.10-second integration time. Percent inhibition was calculated relative to appropriate controls, and ICso values were determined using nonlinear regression analysis with GraphPad Prism 7.0. ICso values were determined based on the ADP-Glo™ luminescence assay and are shown in FIG. 1 (ROCK1: Ml, 2.8 nM; Compound 1, 3.2 nM; Netarsudil, 5.7 nM. ROCK2: Ml, 2.9 nM; Compound 1, 2.7 nM; Netarsudil, 4.7 nM).PKC0 kinase assay

[0051] The inhibitory activity of test compounds against PKCO was measured using the ADP-Glo™ Kinase Assay (Promega), which quantifies luminescence as an indirect measure of ADP production during kinase-catalyzed phosphorylation. The assay was conducted in 384-well plates, with each well containing a 5 pL reaction mixture consisting of kinase buffer (40 mM Tris-HCl, pH 7.5, 20 mM MgCh, 0.01% Triton X-100, 1 mM DTT), 25 pM ATP, and 0.2 pg / pL of CREBtide peptide as the substrate. Recombinant PKCO enzyme was added at 0.6 ng / well, and test compounds dissolved in DMSO were introduced at various concentrations. The enzyme and compound mixture were incubated at room temperature for 5 minutes, followed by the addition of ATP and substrate to initiate the reaction. After a 60-minute incubation in the dark, 5 pL of ADP-Glo™ Reagent was added to terminate the reaction and consume unreacted ATP, followed by a 40-minute incubation. Then, 10 pL of Kinase Detection Reagent was added, and the plate was incubated for an additional 30 minutes at room temperature. Luminescence was detected using aAttorney Docket No.: PPD23-PCTPerkinElmer Ensight plate reader with a 0.10-second integration time. Percent inhibition was calculated relative to positive and negative controls, and ICso values were determined by nonlinear regression analysis using GraphPad Prism 7.0. ICso values were determined based on the ADP-Glo™ luminescence assay and are shown in FIG. 1 (PKCO: Ml, 137.4 nM; Compound 1, 98.2 nM; Netarsudil, 129.6 nM).

[0052] Results from the kinase inhibition assays are presented in FIG. 1. Compound 1 exhibited potent inhibitory activity against both ROCK1 and ROCK2, with ICso values in the low nanomolar range. Specifically, Compound 1 showed comparable potency to Ml against ROCK1, and slightly improved inhibition of ROCK2 compared to both Ml and Netarsudil. In addition, Compound 1 demonstrated greater inhibitory activity against PKCO, with a lower ICso value than those observed for Ml and Netarsudil. These results indicate that Compound 1 possesses a favorable kinase inhibition profile, suggesting its potential utility in treating diseases associated with ROCK1, ROCK2, and PKCO dysregulation.

[0053] ROCK is a clinically validated target for various diseases, including glaucoma, which is a neurodegenerative disease. PKCO is involved in neurodegeneration. Thus, inhibition of both ROCK and PKCO should be more advantageous than inhibition of ROCK alone in the treatment of glaucoma. Accordingly, Compound 1 should be a more potent drug, especially for glaucoma.Liver microsome degradation assay and intrinsic metabolic profiles

[0054] Metabolic stability of the test compounds was evaluated in pooled human and monkey liver microsomes. Microsomal incubations were carried out in phosphate buffer (100 mM, pH 7.4) containing 0.5 mg / mL microsomal protein and 1 pM test compound (Compound 1 or Ml). The reaction mixture was pre-incubated at 37 °C for 5 minutes before initiating the reaction by adding NADPH regeneration solution. Control samples without NADPH were included to account for non-enzymatic degradation. Incubations were conducted at 37 °C and aliquots were collected at 0, 5, 15, 30, and 60 minutes. Reactions were terminated by adding 200 pL of ice-cold methanol: acetonitrile (1:1) containing internal standards (Labetalol and Tolbutamide, each at 50 ng / mL). After centrifugation at 4,000 rpm for 10 minutes, 50 pL of the supernatant was diluted with 150 pL of water and analyzed by LC-MS / MS. Peak areas corresponding to the parent compound determined the percentage remaining over time. First-order degradation rate constants (k) wereAttorney Docket No.: PPD23-PCTcalculated by linear regression of the natural logarithm of the remaining parent drug versus time. The in vitro half-life (ti / 2) was calculated using the formula ti / 2 = 0.693 / k. Intrinsic clearance (CLint, in pL / min / mg protein) was further calculated using the following equation:0.693 incubation volume (uLCLtnt = - x -;ti / 2 protein amount (mg)Species-specific scaling factors were applied to convert in vitro CLint values to in vivo estimates (mL / min / kg), based on microsomal protein per gram of liver and liver weight per kilogram of body weight.Scaling factors for intrinsic clearance prediction in monkey and human Microsomes Species Microsomal Protein Liver Weight Scaling Hepatic Blood Flow (mg / g liver) (g / kg) Factor3(mL / min / kg) Human 20 900 20.745Monkey 30 1350 43.6aScaling Factor = (microsomal protein per gram of liver) x (liver weight per kilogram of body weight)

[0055] Results of monkey and human liver microsome degradation assays are shown in FIG. 2 and FIG. 3. It is clear that Compound 1 is degraded by liver microsome enzymes faster than Ml . That is, the deuterated analog is metabolized faster than the hydrogen analog of the compound. This result is unexpected.

[0056] Based on results from kinase assays and liver microsome degradation assays, Compound 1 is more potent against PKCO while maintaining similar potency against ROCK, as compared with Ml or Netarsudil. ROCK is a clinically validated target for various indications requiring systemic exposure (e.g., oral Fasudil for subarachnoid hemorrhage). However, due to slow degradation (i.e., metabolically stable) of existing drugs, they can have undesired side effects. Compound 1 is more metabolically labile than Ml and Netarsudil. In addition, Compound 1 is a more potent inhibitor than Ml and Netarsudil. These results combined indicate that Compound 1 would be more suitable for treating ROCK or PKC0 associated diseases, especially in systemic setting. In addition to Compound 1, other compounds of Formula (I) also have the same advantageous effects.Attorney Docket No.: PPD23-PCT

[0057] Embodiments of the invention have been described with a limited number of examples. One skilled in the art would appreciate that these examples are for illustration only and other variations and modifications are possible without departing from the scope of the invention. Therefore, the scope of protection should only be limited by the accompanying claims.

Claims

Attorney Docket No.: PPD23-PCTCLAIMSWhat is claimed is:

1. A compound of Formula (I), an enantiomer thereof, a mixture of enantiomers thereof, a racemic mixture thereof, an isotope variant thereof, or a salt thereof, wherein the compound has the following structure:Formula (I)D Dwherein R is hydrogen or R’-CO- wherein R’ is a Ci-Ce alkyl or a Ce-Cio aryl,wherein the Ci-Ce alkyl is a straight-chain alkyl, a branched-chain alkyl, or a cyclic alkyl, andwherein the Ce-Cio aryl is an aromatic moiety with one or more optional substitutions selected from the group consisting of Ci-Ce alkyl, halogen, and OR”, wherein R” is hydrogen or Ci-Ce alkyl.

2. The compound according to claim 1, wherein R is hydrogen.

3. The compound according to claim 1, wherein R is 2,4-dimethylbenzoyl.

4. The compound according to any one of claims 1-3, wherein the compound is an S- enantiomer.

5. A pharmaceutical composition for use in treating a ROCK or PKC0 associated disease, comprising the compound according to any one of claims 1-4 and one or more pharmaceutically acceptable excipients.

6. The pharmaceutical composition according to claim 5, further comprising a second active ingredient.Attorney Docket No.: PPD23-PCT7. The pharmaceutical composition for use in treating ROCK or PKC0 associated diseases according to claim 5, wherein the ROCK or PKC9 associated disease is one selected from the group consisting of cancer, chronic graft-versus-host disease (cGvHD), acute pulmonary disease, chronic pulmonary disease, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, an anterior segment structural disorder, an intraocular pressure- related disorder, a posterior segment disorder, and a corneal or neurotrophic disorder.

8. The pharmaceutical composition for use in treating ROCK or PKC9 associated disease according to claim 7, wherein the ocular disease is one selected from the group consisting of an anterior segment structural disorder and iridocorneal endothelial (ICE) syndrome.

9. The pharmaceutical composition for use in treating ROCK or PKC9 associated disease according to claim 7, wherein the intraocular pressure-related disorder is glaucoma.

10. The pharmaceutical composition for use in treating ROCK or PKC9 associated disease according to claim 7, wherein the posterior segment disorder is one selected from the group consisting of neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

11. The pharmaceutical composition for use in treating ROCK or PKC9 associated disease according to claim 7, wherein the corneal or neurotrophic disorder is one selected from the group consisting of Fuchs endothelial corneal dystrophy (FECD), limbal stem cell deficiency (LSCD), neurotrophic keratitis, corneal endothelial cell dystrophy, corneal neuropathy, corneal nerve regeneration after penetrating eye surgery, and corneal nerve damage after refractive eye surgery.

12. A method for treating a ROCK or PKC9 associated disease, comprising administering to a subject in need thereof the pharmaceutical composition of claim 5.